期刊文献+

长效注射剂释药技术研究进展 被引量:9

Progress of drug delivery technologies for long-acting injections
原文传递
导出
摘要 随着科学技术的不断发展,人们对药物治疗作用的要求越来越高。长效注射剂因可延长药物的作用时间、减少注射次数、改善患者的顺应性而成为当前药剂研究的一大热点。本文以释药技术为主线,综述了前体药物技术、PEG化技术、微球技术、难溶盐技术、注射植入剂、DepoFoam技术、温敏型原位凝胶等释药技术在长效注射剂中的应用。 With the constant development of science and technology, people's demand for drug therapy effect has become higher and higher. Due to the fact that long-acting injection can prolong the action time, reduce the frequency of administration and improve the patient compliance, it has become a hot area of pharmaceutic research. In this review, we introduced sustained-release drug delivery systems and reviewed the application of the technologies such as prodrug, PEGylation, microspheres, insoluble salts technology, injectable implants, Depo- Foam technology and temperature-sensitive in situ gel in the development of long-acting injections.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第5期547-555,共9页 Chinese Journal of New Drugs
基金 国家973课题(2010CB735602 2012CB724002)
关键词 长效注射剂 前体药物技术 PEG化技术 微球技术 DepoFoam技术 long-acting injections prodrug PEGylation microspheres technology DepoFoam technology
  • 相关文献

参考文献57

  • 1CONGRONG L, GANGADHAR S, JOHN BC, et al. Recent ad- vances in prodrugs as drug delivery systems[ J]. Amer J Therap, 2012, 19(1): 33 -43.
  • 2Invega Sustanna Full Prescribing Information[ EB/OL]. [2009 - 05 - 10]. http://www, fda. gov.
  • 3Depo-Testosterone Package Insert: Pharmcia and Upjohn Com- pany [ EB/OL]. [ 2002 - 03 - 04 ]. http ://www. fda. gov.
  • 4ABUCHOWSKI A, VANES T, PALCZUK NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol[ J]. J Biol Chem, 1977, 252 (1): 3578 -3581.
  • 5INADA Y, FURUKAWA M, SASAKI H, et al. Biomedical and biotechnological applications of PEG- and PM- modified proteins [J]. Trends Biotechnol, 1995, 13(3): 86 -91.
  • 6WANG YS, YONGSTER S, GRACE M, et al. Structural and bi- ological characterization of pegylated recombinant interferon al- pha-2b and its therapeutic application[ J]. Adv Drug Deliv Rev, 2002, 54(4) : 547 -570.
  • 7REDDY KR, MODI M W, PEDDER S. Use of peginterferon al- fa-2a (40KD) ( Pegasys ) for the treatment of hepatitis C[ J]. Adv Drug Deliv Rev, 2002, 54(4) : 571 -584.
  • 8ALCONCEL SN, BAAS AS, Maynard HD. FDA-approved poly ( ethylene glycol )-protein conjugate drugs [ J ]. Polym Chem, 2011, 2(7) : 1442 -1448.
  • 9DINNDROF PA, GOOTENBER J, COHEN MH, et al. FDA drug approval summary : pegaspargase ( Oncaspar ) for the first- line treatment of children with acute lymphoblastic leukemia (ALL)[J]. Oncologist, 2007, 12(8): 991 -998.
  • 10路娟,刘清飞,罗国安,王义明.药物的聚乙二醇修饰研究进展[J].有机化学,2009,29(8):1167-1174. 被引量:31

二级参考文献48

共引文献52

同被引文献201

引证文献9

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部